Table III.
Immunological monitoring data and clinical outcome.
| Case | LYMP (/ul) | NLR | CRP (mg/dl) | IL-6 (pg/ml) | IL-8 (pg/ml) | G-MDSC (CD15+DR-CD11b+)/CD15+ | G-MDSC (CD15+DR-CD66b+)/CD15+ | Minimum count of LYMP (/µl) | DTH | ELISPOT (WT1) | HLA tetramer (WT1) | Clinical outcome | PFS/OS (month) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 700 | 1.43 | 0.13 | 1.55 | 5.17 | 10.49 | 11.40 | 510 | − | − | + | PD | 2/4.6 |
| 2 | 1,722 | 3.62 | 2.68 | 4.30 | 2.04 | 4.82 | 9.87 | 384 | + | + | + | PD | 2/7.8 |
| 3 | 1,310 | 2.65 | 0.17 | 1.66 | 3.38 | 6.50 | 6.64 | 610 | + | + | − | PD | 2/5.4 |
| 4 | 462 | 7.55 | 1.69 | 10.67 | 3.87 | 8.66 | 9.90 | 462 | + | + | + | PD | 2/3.7 |
| 5 | 1,221 | 3.04 | 1.46 | 6.59 | 8.42 | 5.63 | 7.01 | 390 | − | + | + | PD | 2/5.3 |
| 6 | 795 | 4.78 | 0.26 | 2.84 | 3.72 | 14.30 | 15.67 | 600 | ND | ND | ND | PD | 1/1.9 |
| 7 | 432 | 14.50 | 1.27 | 7.80 | 10.39 | 7.09 | 9.08 | 216 | − | + | + | SD | 1/1.1 |
| 8 | 2,057 | 1.37 | 0.06 | 0.83 | 2.99 | 9.45 | 17.32 | 713 | ND | − | − | PD | 2/11.6 |
| 9 | 776 | 4.36 | 0.04 | 0.77 | 4.99 | 16.28 | 23.26 | 693 | − | − | − | PD | 3/7.6 |
| 10 | 955 | 6.17 | 5.81 | 15.69 | 17.85 | 15.42 | 39.80 | 593 | ND | ND | ND | PD | 1/4.0 |
LYMP, lymphocyte; NLR, neutrophil ⁄ lymphocyte ratio; CRP, C-reactive protein; IL, interleukin; G-MDSC, Granulocytic myeloid derived suppressor cells; DTH, delayed-type hypersensitivity; ELISPOT, enzyme-linked immunospot; PD, progressive disease; SD, stable disease; PFS, progression free survival; OS, overall survival.